Leishmania infantum: Prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice

Experimental Parasitology

Volumn 118, Issue 3, 2008, Pages 393-401

  Rafati, Sima ^a   Zahedifard, Farnaz ^a   Azari, Mahnaz Kakeh ^b   Taslimi, Yasaman ^a   Taheri, Tahereh ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b UNIVERSITY OF TEHRAN   (Iran)

Author keywords

bovine serum albumin; BSA; C terminal extension of cysteine proteinase type I; CMV; Con A; concanavalin A; CpG; cytomegalovirus; cytosine phosphate guanine oligodeoxynucleotide; deoxyribonucleic acid; DHFR; dihydrofolate reductase; DNA; E. coli; Escherichia coli; F T; frozen and thawed; His; histidine; IFN ; IgG; IL 5; Immunogenicity; immunoglobulin G; interferon gamma; interleukin 5; IPTG; isopropyl d 1 thiogalactopyranoside; L. infantum; LB; Luria Bertani; Ni NTA; nickel nitrilotriacetic acid; O phenylenediamine; OPD; PBMC; PBS; peripheral blood mononuclear cell; phosphate buffer saline; SDS PAGE; sodium dodecyl sulfate polyacrylamide gel electrophporesis; T helper; TH

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE 1; FREUND ADJUVANT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 5; MONTANIDE 720; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGENICITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; EXPERIMENTAL INFECTION; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; LEISHMANIA INFANTUM; LEISHMANIASIS; LIVER; MOUSE; NONHUMAN; PARASITEMIA; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROVOCATION TEST; REVACCINATION; SPLEEN;

ANIMALS; ANTIBODIES, PROTOZOAN; BLOTTING, WESTERN; CYSTEINE ENDOPEPTIDASES; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; INTERFERON TYPE II; INTERLEUKIN-5; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; LIVER; MICE; MICE, INBRED BALB C; PROTOZOAN VACCINES; SPLEEN; VACCINES, DNA;

BOVINAE; CYTOMEGALOVIRUS; ESCHERICHIA COLI; LEISHMANIA INFANTUM; LURIA; MURINAE; MUS;

EID: 38649134178     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2007.10.004     Document Type: Article

References (30)

1. Barbieri C.L. Immunology of canine leishmaniasis. Parasite Immunology 28 (2006) 329-337
2. Beyrodt C.G., Pinto A.R., Freymuller E., and Barbieri C.L. Characterization of an antigen from Leishmania amazonensis amastigotes able to elicit protective responses in a murine model. Infection and Immunity 65 (1997) 2052-2059
3. Buffet P.A., Sulahian A., Garin Y.J.F., Nassar N., and Derouin F. Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice. Antimicrobial Agents Chemotherapy (1995) 2167-2618
4. Coler R.N., Skeiky Y.A., Bernards K., et al. Immunization with a polyprotein vaccine consisting of the T cell antigens thiol-specific antioxidant, Leishmania major stress inducible protein-1 and Leishamina elongation initiation factor protects against leishmaniasis. Infection and Immunity 70 (2002) 4215-4225
5. Coombs G.H., and Mottram J.C. Proteinases of trypanosomes and Leishmania: biology and control (1998), Oxford CAB International, London, UK pp. 177-179
6. Day M.J. Immunoglobulin G subclass distribution in canine leishmaniasis: a review and analysis of pitfalls in interpretation. Veterinary Parasitology (2007) 2-8
7. Gramiccia M., and Gradoni L. The current status of zoonotic leishmaniasis and approaches to disease control. International Journal of Parasitology 35 (2005) 1169-1180
8. Gurunathan S., Sacks D.L., Brown D.R., and Seder R.A. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. Journal of Experimental Medicine 186 (1997) 1137-1147
9. Handman E., Symons F.M., Baldwin T.M., Curtis J.M., and Scheerlinck J.P. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response. Infection and Immunity 63 (1995) 4261-4267
10. Huete-Perez J., Engel J., Brinen L., Mottram J.C., and McKerrow J. Protease trafficking in two primitive eukaryotes is mediated by a prodomain protein motif. Journal of Biological Chemistry 274 (1999) 16249-16256
11. McMahon-Pratt D., Rodriguez D., Rodriguez J.R., Zhang Y., Manson K., Bergman C., Rivas L., Rodriguez J.F., Lohman K.L., Ruddle NH., et al. Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection. Infection and Immunity 61 (1993) 3351-3359
12. Melby P.C., Yang J., Zhao W., Perez L., and Cheng J. Leishmania donovani p36 (LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infection and Immunity 69 (2001) 4719-4725
13. Mendez S., Belkaid Y., Seder R.A., and Sacks D. Optimization of DNA vaccination against cutaneous leishmaniasis. Vaccine (2002) 3702-3708
14. Mottram J.C., North M.J., Barry J.D., and Coombs G.H. A cysteine proteinase cDNA from Trypanosoma brucei predicts an enzyme with an unusual C-terminal extension. FEBS Letters 258 (1989) 211-215
15. Mottram J.C., Coombs G.H., and Alexander J. Cysteine peptidases as virulence factors of Leishmania. Current Opinion in Microbiology 7 (2004) 375-381
16. Nakhaee A.R., Taheri T., Taghikhani M., Mohebali M., Salmanian A.H., Fasel N., and Rafati S. Humoral and cellular immune responses against Type I cysteine proteinase of Leishmania infantum are higher in asymptomatic than symptomatic dogs selected from a naturally infected population. Veterinary Parasitology 119 (2004) 107-123
17. Ortiz M.L., Calero M., Patron C.F., Castellanos L., and Mendez E. Imidazole-SDS-Zn reverse staining of proteins in gels containing or not SDS and microsequencing of individual unmodified electroblotted proteins. FEBS Letters 296 (1992) 300-304
18. Pascalis H., Lavergne A., Bourreau E., Kariminia A., Pradinaud R., Rafati S., and Launois P. Cell development induced by cysteine proteinases A and B in localized cutaneous leishmaniasis due to Leishmania guyanensis. Infection and Immunity 71 (2003) 2924-2926
19. Pollock K.G., McNeil K.S., Mottram J.C., Lyons R.E., Brewer J.M., Scott P., Coombs G.H., and Alexander J. The Leishmania mexicana cysteine protease, CPB 2.8, induces potent Th2 responses. Journal of Immunology 170 (2003) 1746-1753
20. Poot J., Spreeuwenberg K., Sanderson S.J., Schijins V.E., Mottram J.C., Coombs G.H., and Vermeulen A.N. Vaccination with a preparation based on recombinant cysteine peptidases and canine IL-12 does not protect dogs from infection with Leishmania infantum. Vaccine 24 (2006) 2460-2468
21. Rafati S., Baba A.A., Bakhshayesh M., and Vafa M. Vaccination of BALB/c mice with Leishmania major amastigote-specific cysteine proteinase. Clinical Experimental Immunology 120 (2000) 34-38
22. Rafati S., Salmanian A.H., Taherei T., Vafa M., and Fasel N. A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major. Vaccine 19 (2001) 3369-3375
23. Rafati S., Fasel N., and Masina S. Leishmania cysteine proteinases: from gene to subunit vaccine. Current Genomics 4 (2003) 109-121
24. + T lymphocyte activation. Vaccine 20 (2002) 2439-2447
25. Rafati S., Nakhaee A., Taheri T., Taslimi Y., Darabi H., Eravani D., Sanos S., Kaye P., Taghikjani M., Jamshidi S., and Rad M.A. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine 23 (2005) 3716-3725
26. Rafati S., Zahedifard F., and Nazgouee F. Prime boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine 24 (2006) 2169-2175
27. Sanderson S., Pollock K., Hilley J., Meldal M., Hilaire P., Juliano L., Mottram J.C., and Coombs G. Expression and characterization of a recombinant cysteine proteinase of Leishmania mexicana. Biochemistry Journal 374 (2000) 383-388
28. Serezani C.H., Franco A.R., Waji M., Umada Y., Wunderlich G., Borges M.M., and Uliana S.R. Evaluation of the murine immune response to Leishmania meta 1 antigen delivered as recombinant protein or DNA vaccine. Vaccine 20 (2002) 3755-3763
29. Skeiky Y.A., Kennedy M., and Kaufman D. LeIF: a recombinant Leishmania protein that induces an IL-12 mediated Th1 cytokine profile. Journal of Immunology. 161 (1998) 6171-6179
30. Solioz N., Blum-Tirouvanziam U., Raymond J., Rafati S., Corradin G., Mauel J., and Fasel N. The protective capacities of a nuclear antigen against experimental murine cutaneous leishmaniasis. Vaccine 18 (1999) 850-859